Specify a stock or a cryptocurrency in the search bar to get a summary
Initiator Pharma A/S
INITInitiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes IPED2015, a drug candidate which is in clinical phase 2a for the treatment of organic erectile dysfunction; IP2018, a monoamine reuptake inhibitor completed Phase IIa for the treatment of psychogenic erectile dysfunction primarily targeting the serotonin followed by the dopamine system; and IPTN2021, a Phase 1 clinical drug program targeting an orphan drug indication in severe neuropathic pain, and trigeminal neuralgia. The company also developing IP2017, a proprietary triple reuptake inhibitor; and IP2016, a preclinical development for the treatment of depression. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark. Address: Ole Maaloes vej 3, Copenhagen, Denmark, 2200
Analytics
WallStreet Target Price
264.61 SEKP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures INIT
Dividend Analytics INIT
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History INIT
Stock Valuation INIT
Financials INIT
Results | 2019 | Dynamics |